DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia

Recruiting

Conditions: Dengue Fever

Interventions: Other: No Intervention

First Posted Date: 2024-04-29

Last Posted Date: 2024-10-17

Lead Sponsor: Takeda

Target Recruit Count: 10000

Registration Number: NCT06388785

Locations: 🇲🇾
Universiti Putra Malaysia, Serdang, Selangor, Malaysia
🇲🇾
Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

Phase 1

Withdrawn

Conditions: Refractory Lupus Nephritis
Refractory Systemic Sclerosis

Interventions: Biological: TAK-007
Drug: Chemotherapy Agents

First Posted Date: 2024-04-22

Last Posted Date: 2025-04-06

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06377228

Locations: 🇺🇸
University of Texas Health Science Center, Houston, Texas, United States

A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China

Recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Other: No intervention

First Posted Date: 2024-04-04

Last Posted Date: 2025-03-14

Lead Sponsor: Takeda

Target Recruit Count: 130

Registration Number: NCT06346899

Locations: 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujan, China
🇨🇳
The First Affiliated Hospital ,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 10 locations

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Phase 3

Recruiting

Conditions: Generalized Pustular Psoriasis
Erythrodermic Psoriasis

Interventions: Drug: TAK-279

First Posted Date: 2024-03-21

Last Posted Date: 2025-01-10

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06323356

Locations: 🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan
🇯🇵
Fujita Health University Hospital, Toyoake, Aichi, Japan
🇯🇵
Kimitsu Chuo Hospital, Kisarazu, Chiba, Japan

and more 17 locations

A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Repaglinide
Drug: Midazolam
Drug: TAK-279

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-23

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06290050

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Budesonide

First Posted Date: 2024-02-20

Last Posted Date: 2024-12-02

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT06268301

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-279
Drug: TAK-279 Placebo
Drug: Moxifloxacin
Drug: Moxifloxacin Placebo

First Posted Date: 2024-02-14

Last Posted Date: 2024-07-11

Lead Sponsor: Takeda

Target Recruit Count: 120

Registration Number: NCT06258265

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: TAK-279
Drug: Placebo

First Posted Date: 2024-02-12

Last Posted Date: 2025-05-16

Lead Sponsor: Takeda

Target Recruit Count: 207

Registration Number: NCT06254950

Locations: 🇺🇸
GastroIntestinal BioSciences, Los Angeles, California, United States
🇺🇸
United Medical Doctors, Murrieta, California, United States
🇺🇸
UCI Health, Orange, California, United States

and more 173 locations

A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation

Not yet recruiting

Conditions: Cytomegalovirus (CMV)
Kidney Failure
Kidney Disease

Interventions: Other: No Intervention

First Posted Date: 2024-02-06

Last Posted Date: 2024-05-03

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT06243731

A First-In-Human Study of TAK-004 in Healthy Adults

Phase 1

Recruiting

Conditions: Healthy Volunteers

Interventions: Drug: TAK-004
Drug: Placebo

First Posted Date: 2024-02-01

Last Posted Date: 2025-04-24

Lead Sponsor: Takeda

Target Recruit Count: 240

Registration Number: NCT06236009

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy